Bio News
The US Food and Drug Administration (FDA) has approved Elecsys pTau217, an Alzheimer’s blood test developed by Roche and Eli Lilly. Roche said the single-biomarker test helps assess the likelihood of pathology early in the diagnostic pathway by identifying amyloid plaque accumulation in patients aged 55 and older who show signs of cognitive decline. Labcorp and Quest Diagnostics plan to introduce the test nationwide within the next several months and launch it under the AD-Detect brand in the fourth quarter, respectively.
BIOBOOK TEAM
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
